StockSelector.com
  Research, Select, & Monitor Tuesday, December 18, 2018 10:40:45 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Johnson & Johnson$130.42$1.28.99%

  Quote | Ranking | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

 Johnson & Johnson Reports 2017 Fourth-Quarter Results:
   Tuesday, January 23, 2018 6:40:00 AM ET

Johnson & Johnson (JNJ ) today announced sales of $20.2 billion for the fourth quarter of 2017, an increase of 11.5% as compared to the fourth quarter of 2016. Operational sales results increased 9.4% and the positive impact of currency was 2.1%. Domestic sales increased 9.8%. International sales increased 13.5%, reflecting operational growth of 9.0% and a positive currency impact of 4.5%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales for the fourth quarter of 2017 increased 4.2%, domestic sales increased 4.1% and international sales increased 4.3%.*

Worldwide sales for the full-year 2017 were $76.5 billion, an increase of 6.3% versus 2016. Operational results increased 6.0% and the positive impact of currency was 0.3%. Domestic sales increased 5.4%. International sales increased 7.4%, reflecting operational growth of 6.6% and a positive currency impact of 0.8%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales for the full-year 2017 increased 2.4%, domestic sales increased 1.6% and international sales increased 3.3%.*

Net loss and diluted loss per share for the fourth quarter of 2017 were $10.7 billion and $3.99, respectively. Fourth-quarter 2017 net loss included after-tax intangible amortization expense of approximately $0.9 billion and a net charge for after-tax special items of approximately $14.6 billion. Included in these special items is a provisional amount of approximately $13.6 billion associated with the recent enactment of tax legislation.** Fourth-quarter 2016 net earnings included after-tax intangible amortization expense of approximately $0.3 billion and a net charge for after-tax special items of approximately $0.3 billion. Excluding after-tax intangible amortization expense and special items, adjusted net earnings for the current quarter were $4.8 billion and adjusted diluted earnings per share were $1.74, representing increases of 9.5% and 10.1%, respectively, as compared to the same period in 2016.* On an operational basis, adjusted diluted earnings per share increased 5.7%.* A reconciliation of non-GAAP financial measures is included as an accompanying schedule.

Net earnings and diluted earnings per share for the full-year 2017 were $1.3 billion and $0.47, respectively. Full-year net earnings included after-tax intangible amortization expense of approximately $2.5 billion and a charge for after-tax special items of approximately $16.2 billion. Included in these special items is a provisional amount of approximately $13.6 billion associated with the recent enactment of tax legislation.** Full-year 2016 net earnings included after-tax intangible amortization expense of approximately $0.9 billion and a charge for after-tax special items of approximately $1.3 billion. Excluding after-tax intangible amortization expense and special items, adjusted net earnings for the full-year of 2017 were $20.0 billion and adjusted diluted earnings per share were $7.30, representing increases of 6.8% and 8.5%, respectively, as compared to the same period in 2016.* On an operational basis, adjusted diluted earnings per share also increased 7.6%.* A reconciliation of non-GAAP financial measures is included as an accompanying schedule.

"Johnson & Johnson delivered strong adjusted earnings per share growth of 8.5% and total shareholder return of greater than 24% in 2017, driven by the robust performance of our Pharmaceutical business, while continuing to make investments in acquisitions, innovation and strategic partnerships to accelerate growth in each of our businesses," said Alex Gorsky, Chairman and Chief Executive Officer. "As we enter 2018 and look beyond, we are experiencing an incredible pace of change in health care. Johnson & Johnson is uniquely positioned to lead during this dynamic era and deliver innovative solutions for patients and consumers that drive sustainable, long-term growth. We are pleased with the passage of recent legislation modernizing the U.S. tax system, which enables Johnson & Johnson to invest in innovation at higher levels to help address the most challenging unmet medical needs facing health care today."

Mr. Gorsky continued, "I want to thank all of our talented colleagues for their commitment, passion and dedication to transforming the lives of patients and consumers worldwide."

The Company announced its 2018 full-year guidance for sales of $80.6 billion to $81.4 billion reflecting expected operational growth in the range of 3.5% to 4.5%. The Company also announced adjusted earnings guidance for full-year 2018 of $8.00 to $8.20 per share reflecting expected operational growth in the range of 6.8% to 9.6%.* Adjusted earnings guidance excludes the impact of after-tax intangible amortization expense and special items.

Segment Sales Performance Worldwide Consumer sales of $13.6 billion for the full-year 2017 represented an increase of 2.2% versus the prior year, consisting of an operational increase of 1.3% and a positive impact from currency of 0.9%. Domestic sales increased 2.7%; international sales increased 1.9%, which reflected an operational increase of 0.4% and a positive currency impact of 1.5%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales decreased 0.5%, domestic sales decreased 0.7% and international sales decreased 0.3%*.

Worldwide operational results, excluding the net impact of acquisitions and divestitures, were negatively impacted by declines in the Baby Care and Oral Care businesses, mostly offset by growth in over-the-counter products, including TYLENOL? analgesics and upper respiratory products, and NEUTROGENA? beauty products.

Worldwide Pharmaceutical sales of $36.3 billion for the full-year 2017 represented an increase of 8.3% versus the prior year with an operational increase of 8.0% and a positive impact from currency of 0.3%. Domestic sales increased 6.7%; international sales increased 10.8%, which reflected an operational increase of 10.1% and a positive currency impact of 0.7%. Sales included the impact of the acquisition of Actelion Ltd. which was completed in June 2017 and contributed 4.2% to worldwide operational sales growth. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 4.2%, domestic sales increased 3.1% and international sales increased 5.8%.* Worldwide operational sales growth was negatively impacted by approximately 1.8 points due to a positive adjustment of U.S. rebate accruals in the first half of 2016, which did not repeat in the first half of 2017.

Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by new products and the strength of core products. Strong growth in new products include DARZALEX? (daratumumab), for the treatment of patients with multiple myeloma, IMBRUVICA? (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer and TREMFYA? (guselkumab), for the treatment of adults living with moderate to severe plaque psoriasis.

Additional contributors to operational sales growth included STELARA? (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, INVEGA? SUSTENNA?/XEPLION?/TRINZA? (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, ZYTIGA? (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer, and XARELTO? (rivaroxaban), an oral anticoagulant, partially offset by declines in REMICADE? (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases, due to biosimilar entrants.

During the quarter, the U.S. Food and Drug Administration (FDA) approved JULUCA? (rilpivirine and dolutegravir), the first, complete, single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection; a 10 mg once-daily dose of XARELTO? (rivaroxaban) for reducing the continued risk for recurrent venous thromboembolism after completing at least six months of initial anticoagulation therapy; and SIMPONI ARIA? (golimumab) for the treatment of adults with active psoriatic arthritis or active ankylosing spondylitis. The European Commission approved TREMFYA? (guselkumab) for the treatment of adults with moderate to severe plaque psoriasis and granted approval to broaden the existing marketing authorization for ZYTIGA? (abiraterone acetate) plus prednisone / prednisolone to include the treatment of newly-diagnosed high-risk metastatic hormone-sensitive prostate cancer.

Regulatory applications for approval were submitted to the FDA and European Medicines Agency to expand the current indication of DARZALEX? (daratumumab) for use in combination with bortezomib, melphalan and prednisone, as a treatment for newly diagnosed patients with multiple myeloma ineligible for autologous stem cell transplantation. In addition, a supplemental New Drug Application was submitted to the FDA for two new XARELTO? (rivaroxaban) vascular indications: reducing the risk of major cardiovascular (CV) events such as CV death, heart attack or stroke in patients with chronic coronary and/or peripheral artery disease (CAD/PAD), and for reducing the risk of acute limb ischemia in patients with PAD.

Also in the quarter, a worldwide collaboration and license agreement was executed with Legend Biotech, a subsidiary of GenScript Biotech Corporation, to develop, manufacture and commercialize a chimeric antigen receptor (CAR) T-cell therapy, LCAR-B38M, targeting BCMA for the treatment of multiple myeloma.

Worldwide Medical Devices sales of $26.6 billion for the full-year 2017 represented an increase of 5.9% versus the prior year consisting of an operational increase of 5.7% and a positive currency impact of 0.2%. Domestic sales increased 4.5%; international sales increased 7.1%, which reflected an operational increase of 6.7% and a positive currency impact of 0.4%. Sales included the impact of the acquisition of Abbott Medical Optics which contributed 4.5%, to worldwide operational sales growth. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 1.5%, domestic sales were flat and international sales increased 3.0%.*

Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by electrophysiology products in the Cardiovascular business; endocutters and biosurgicals in the Advanced Surgery business; ACUVUE? contact lenses in the Vision Care business; and wound closure products in the General Surgery business, partially offset by declines in the Diabetes Care business and spine products in the Orthopaedics business.

About Johnson & Johnson At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

* Operational sales growth excluding the net impact of acquisitions and divestitures, as well as adjusted net earnings, adjusted diluted earnings per share and operational adjusted diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company’s website at www.investor.jnj.com. Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson’s results computed in accordance with GAAP.

** The provisional estimates are based on the Company’s initial analysis of the Tax Cuts and Jobs Act (the "Act") as of January 18, 2018. Given the significant complexity of the Act, anticipated guidance from the U. S. Treasury about implementing the Act, and the potential for additional guidance from the Securities and Exchange Commission or the Financial Accounting Standards Board related to the Act, these estimates may be adjusted during 2018.

Johnson & Johnson will conduct a conference call with investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can be found on the company’s website at www.investor.jnj.com.

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic and financial market factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; significant adverse litigation or government action, including related to product liability claims and allegations concerning opioid marketing practices; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; increased scrutiny of the health care industry by government agencies; and the potential failure to meet obligations in compliance agreements with government bodies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2017, including under "Item 1A. Risk Factors," its most recently filed Quarterly Report on Form 10-Q, including in the section captioned "Cautionary Note Regarding Forward-Looking Statements," and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)   FOURTH QUARTER                                    TWELVE MONTHS
                                                      Percent Change                                    Percent Change
                                   2017       2016    Total    Operations  Currency  2017       2016    Total    Operations  Currency
Sales to customers by
segment of business
Consumer
U.S.                               $   1,379  1,387   (0.6) %  (0.6)       -         $   5,565  5,420   2.7   %  2.7         -
International                      2,161      2,045   5.7      1.2         4.5       8,037      7,887   1.9      0.4         1.5
                                   3,540      3,432   3.1      0.4         2.7       13,602     13,307  2.2      1.3         0.9
Pharmaceutical
U.S.                               5,776      5,002   15.5     15.5        -         21,474     20,125  6.7      6.7         -
International                      3,905      3,230   20.9     15.5        5.4       14,782     13,339  10.8     10.1        0.7
                                   9,681      8,232   17.6     15.5        2.1       36,256     33,464  8.3      8.0         0.3
Medical Devices
U.S.                               3,314      3,148   5.3      5.3         -         12,824     12,266  4.5      4.5         -
International                      3,660      3,294   11.1     7.5         3.6       13,768     12,853  7.1      6.7         0.4
                                   6,974      6,442   8.3      6.5         1.8       26,592     25,119  5.9      5.7         0.2
U.S.                               10,469     9,537   9.8      9.8         -         39,863     37,811  5.4      5.4         -
International                      9,726      8,569   13.5     9.0         4.5       36,587     34,079  7.4      6.6         0.8
Worldwide                          $ 20,195   18,106  11.5  %  9.4         2.1       $ 76,450   71,890  6.3   %  6.0         0.3
Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)   FOURTH QUARTER                                   TWELVE MONTHS
                                                     Percent Change                                   Percent Change
                                   2017      2016    Total    Operations  Currency  2017      2016    Total    Operations Currency
Sales to customers by
geographic area
U.S.                               $ 10,469  9,537   9.8   %  9.8         -         $ 39,863  37,811  5.4   %  5.4        -
Europe                             4,728     4,001   18.2     10.1        8.1       17,126    15,770  8.6      7.2        1.4
Western Hemisphere excluding U.S.  1,519     1,465   3.7      1.8         1.9       6,041     5,734   5.4      2.8        2.6
Asia-Pacific, Africa               3,479     3,103   12.1     11.1        1.0       13,420    12,575  6.7      7.5        (0.8)
International                      9,726     8,569   13.5     9.0         4.5       36,587    34,079  7.4      6.6        0.8
Worldwide                          $ 20,195  18,106  11.5  %  9.4         2.1       $ 76,450  71,890  6.3   %  6.0        0.3
Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)                             FOURTH QUARTER
                                                                              2017                                         2016                             Percent
                                                                                                     Percent                                      Percent   Increase
                                                                              Amount                 to Sales              Amount                 to Sales  (Decrease)
Sales to customers                                                            $  20,195              100.0                 $ 18,106               100.0     11.5
Cost of products sold                                                         7,243                  35.9                  5,534                  30.5      30.9
Selling, marketing and administrative expenses                                6,025                  29.8                  5,309                  29.3      13.5
Research and development expense                                              3,635                  18.0                  2,640                  14.6      37.7
In-process research and development                                           408                    2.0                   -                      -
Interest (income) expense, net                                                189                    0.9                   84                     0.5
Other (income) expense, net                                                   (9)                    0.0                   20                     0.1
Restructuring                                                                 144                    0.7                   195                    1.1
Earnings before provision for taxes on income                                 2,560                  12.7                  4,324                  23.9      (40.8)
Provision for taxes on income                                                 13,273                 65.7                  510                    2.8
Net earnings/(Loss)                                                           $ (10,713)             (53.0)                $   3,814              21.1      (380.9)
Net earnings/(Loss) per share (Basic/Diluted)*                                $     (3.99)                                 $     1.38                       (389.1)
Average shares outstanding (Basic/Diluted)*                                   2,684.9                                      2,764.5
Effective tax rate                                                            518.5                %                       11.8                 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income                                 $    5,251             26.0                  $   5,103              28.2      2.9
Net earnings                                                                  $    4,777             23.7                  $   4,361              24.1      9.5
Net earnings per share (Diluted)                                              $      1.74                                  $     1.58                       10.1
Average shares outstanding (Diluted)**                                        2,740.7                                      2,764.5
Effective tax rate                                                            9.0                  %                       14.5                 %
*Basic shares are used to calculate loss per share as use of diluted shares when in a loss position would be anti-dilutive.
**Difference of 55.8 shares due to anti-dilutive impact on net loss position.
(1)See Reconciliation of Non-GAAP Financial Measures.
Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)                 TWELVE MONTHS
                                                                  2017                   2016                   Percent
                                                                               Percent                Percent   Increase
                                                                  Amount       to Sales  Amount       to Sales  (Decrease)
Sales to customers                                                $ 76,450     100.0     $ 71,890     100.0     6.3
Cost of products sold                                             25,354       33.2      21,685       30.2      16.9
Selling, marketing and administrative expenses                    21,420       28.0      19,945       27.7      7.4
Research and development expense                                  10,554       13.8      9,095        12.7      16.0
In-process research and development                               408          0.6       29           0.0
Interest (income) expense, net                                    549          0.7       358          0.5
Other (income) expense, net                                       183          0.2       484          0.7
Restructuring                                                     309          0.4       491          0.7
Earnings before provision for taxes on income                     17,673       23.1      19,803       27.5      (10.8)
Provision for taxes on income                                     16,373       21.4      3,263        4.5       401.8
Net earnings                                                      $   1,300    1.7       $ 16,540     23.0      (92.1)
Net earnings per share (Diluted)                                  $     0.47             $     5.93             (92.1)
Average shares outstanding (Diluted)                              2,745.3                2,788.9
Effective tax rate                                                92.6       %           16.5       %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income                     $ 24,212     31.7      $ 22,759     31.7      6.4
Net earnings                                                      $ 20,040     26.2      $ 18,764     26.1      6.8
Net earnings per share (Diluted)                                  $     7.30             $     6.73             8.5
Effective tax rate                                                17.2       %           17.6       %
(1)See Reconciliation of Non-GAAP Financial Measures.
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
                                                                  Fourth Quarter                         % Incr. /      Twelve Months             % Incr. /
(Dollars in Millions Except Per Share Data)                       2017                      2016         (Decr.)        2017         2016         (Decr.)
Earnings before provision for taxes on income - as reported       $    2,560                4,324        (40.8)      %  $ 17,673     19,803       (10.8)                %
Intangible asset amortization expense                             1,077                     344                         2,963        1,271
Litigation expense, net                                           645                       96                          1,256        817
Actelion acquisition related cost                                 217                       -                           797          -
Restructuring/Other (1)                                           284                       298                         760          685
In-process research and development                               408                       -                           408          29
Diabetes asset impairment                                         35                        -                           215          -
AMO acquisition related cost                                      25                        -                           140          -
DePuy ASR(TM) Hip program                                         -                         9                           -            9
Other                                                             -                         32                          -            145
Earnings before provision for taxes on income - as adjusted       $    5,251                5,103        2.9         %  $ 24,212     22,759       6.4                   %
Net Earnings/(Loss) - as reported                                 $ (10,713)                3,814        (380.9)     %  $   1,300    16,540       (92.1)                %
Impact of tax legislation                                         13,556                    -                           13,556       -
Intangible asset amortization expense                             926                       252                         2,481        931
Litigation expense, net                                           506                       80                          955          675
Actelion acquisition related cost                                 313                       -                           767          -
Restructuring/Other                                               237                       251                         595          544
In-process research and development                               266                       -                           266          23
Diabetes asset impairment                                         (116)                     -                           4            -
AMO acquisition related cost                                      (198)                     -                           116          -
DePuy ASR(TM) Hip program                                         -                         7                           -            7
Other                                                             -                         (43)                        -            44
Net Earnings - as adjusted                                        $    4,777                4,361        9.5         %  $ 20,040     18,764       6.8                   %
Diluted Net Earnings/(Loss) per share - as reported               $     (3.99)              1.38         (389.1)     %  $     0.47   5.93         (92.1)                %
Dilutive impact of shares excluded due to net loss position       0.08                      -                           -            -
Impact of tax legislation                                         4.94                      -                           4.94         -
Intangible asset amortization expense                             0.34                      0.09                        0.90         0.33
Litigation expense, net                                           0.19                      0.03                        0.35         0.24
Actelion acquisition related cost                                 0.11                      -                           0.28         -
Restructuring/Other                                               0.08                      0.09                        0.22         0.20
In-process research and development                               0.10                      -                           0.10         0.01
Diabetes asset impairment                                         (0.04)                    -                           -            -
AMO acquisition related cost                                      (0.07)                    -                           0.04         -
DePuy ASR(TM) Hip program                                         -                         -                           -            -
Other                                                             -                         (0.01)                      -            0.02
Diluted Net Earnings per share - as adjusted                      $      1.74               1.58         10.1        %  $     7.30   6.73         8.5                   %
Operational Diluted Net Earnings per share - as adjusted at 2015                            1.59                                     6.78
foreign currency exchange rates
Impact of currency at 2016 foreign currency exchange rates        (0.07)                    (0.01)                      (0.06)       (0.05)
Operational Diluted Net Earnings per share - as adjusted at 2016  $      1.67               1.58         5.7         %  $     7.24   6.73         7.6                   %
foreign currency exchange rates
(1) Includes $42M recorded in cost of products sold and $98M recorded in other (income) expense for the fourth quarter 2017, and $18M recorded in cost of products sold
and $85M recorded in other (income) expense for the fourth quarter 2016.
Includes $88M recorded in cost of products sold and $363M recorded in other (income) expense for twelve months YTD 2017, and $45M recorded in cost of products sold
and $149M recorded in other (income) expense for twelve months YTD 2016.
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Operational Sales Growth Excluding Acquisitions and Divestitures
FOURTH QUARTER 2017 ACTUAL vs. 2016 ACTUAL
Segments
                                                                     Consumer  Pharmaceutical  Medical Devices  Total
                                                                     Operational % (1)
WW As Reported:                                                      0.4%      15.5%           6.5%             9.4%
U.S.                                                                 (0.6)%    15.5%           5.3%             9.8%
International                                                        1.2%      15.5%           7.5%             9.0%
Vision Care
Abbott Medical Optics                                                                          (5.4)            (1.9)
U.S.                                                                                           (4.9)            (1.7)
International                                                                                  (5.8)            (2.2)
Pulmonary Hypertension
Actelion                                                                       (7.4)                            (3.4)
U.S.                                                                           (7.3)                            (3.8)
International                                                                  (7.6)                            (2.8)
Cardiovascular / Metabolism / Other
Actelion                                                                       (0.5)                            (0.2)
U.S.                                                                           (0.3)                            (0.2)
International                                                                  (0.7)                            (0.3)
Spine & Other                                                                                  1.2              0.5
Codman Neuroscience                                                                            0.8              0.2
U.S.                                                                                           1.6              0.6
International
All Other Acquisitions and Divestitures                              (0.2)                     (0.3)            (0.2)
U.S.                                                                 0.0                       (0.9)            (0.2)
International                                                        (0.5)                     0.3              0.0
WW Ops excluding Acquisitions and Divestitures                       0.2%      7.6%            2.0%             4.2%
U.S.                                                                 (0.6)%    7.9%            0.3%             4.1%
International                                                        0.7%      7.2%            3.6%             4.3%
(1)Operational growth excludes the effect of translational currency
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Operational Sales Growth Excluding Acquisitions and Divestitures
TWELVE MONTHS 2017 ACTUAL vs. 2016 ACTUAL
Segments
                                                                     Consumer  Pharmaceutical  Medical Devices  Total
                                                                     Operational % (1)
WW As Reported:                                                      1.3%      8.0%            5.7%             6.0%
U.S.                                                                 2.7%      6.7%            4.5%             5.4%
International                                                        0.4%      10.1%           6.7%             6.6%
Beauty
Vogue                                                                (1.5)                                      (0.3)
U.S.                                                                 (3.1)                                      (0.4)
International                                                        (0.4)                                      (0.1)
Other Neuroscience
Controlled Substance Raw Material and API Business                             0.4                              0.2
U.S.                                                                           0.5                              0.2
International                                                                  0.2                              0.1
Diagnostics
Ortho-Clinical Diagnostics                                                                     0.2              0.0
U.S.                                                                                           0.0              0.0
International                                                                                  0.5              0.1
Beauty
Dr. Ci: Labo                                                         (0.3)                                      (0.1)
U.S.                                                                 0.0                                        0.0
International                                                        (0.6)                                      (0.1)
Vision Care
Abbott Medical Optics                                                                          (4.5)            (1.5)
U.S.                                                                                           (4.0)            (1.3)
International                                                                                  (4.9)            (1.8)
Pulmonary Hypertension
Actelion                                                                       (4.0)                            (1.9)
U.S.                                                                           (3.8)                            (2.0)
International                                                                  (4.2)                            (1.7)
Cardiovascular / Metabolism / Other
Actelion                                                                       (0.2)                            (0.1)
U.S.                                                                           (0.3)                            (0.1)
International                                                                  (0.3)                            (0.1)
Spine & Other
Codman Neuroscience                                                                            0.3              0.1
U.S.                                                                                           0.2              0.1
International                                                                                  0.5              0.2
All Other Acquisitions and Divestitures                              0.0                       (0.2)            0.0
U.S.                                                                 (0.3)                     (0.7)            (0.3)
International                                                        0.3                       0.2              0.1
WW Ops excluding Acquisitions and Divestitures                       (0.5)%    4.2%            1.5%             2.4%
U.S.                                                                 (0.7)%    3.1%            0.0%             1.6%
International                                                        (0.3)%    5.8%            3.0%             3.3%
(1)Operational growth excludes the effect of translational currency
                                                 REPORTED SALES vs. PRIOR PERIOD ($MM)
                                              FOURTH QUARTER                                                             TWELVE MONTHS
                                                                                      % Change                                                                             % Change
                                                 2017             2016                Reported Operational (1) Currency     2017                    2016                   Reported Operational (1) Currency
CONSUMER SEGMENT (2)
BABY CARE
US                                               $           123  $               123 0.0%     0.0%            -            $                  449  $                  488 -8.0%    -8.0%           -
Intl                                             367              370                 -0.8%    -3.2%           2.4%         1,467                   1,513                  -3.0%    -3.6%           0.6%
WW                                               490              493                 -0.6%    -2.4%           1.8%         1,916                   2,001                  -4.2%    -4.7%           0.5%
BEAUTY
US                                               596              580                 2.8%     2.8%            -            2,335                   2,135                  9.4%     9.4%            -
Intl                                             514              483                 6.4%     2.0%            4.4%         1,865                   1,762                  5.8%     4.5%            1.3%
WW                                               1,110            1,063               4.4%     2.4%            2.0%         4,200                   3,897                  7.8%     7.2%            0.6%
ORAL CARE
US                                               156              163                 -4.3%    -4.3%           -            616                     648                    -4.9%    -4.9%           -
Intl                                             237              234                 1.3%     -2.6%           3.9%         915                     920                    -0.5%    -1.8%           1.3%
WW                                               393              397                 -1.0%    -3.3%           2.3%         1,531                   1,568                  -2.4%    -3.2%           0.8%
OTC
US                                               406              418                 -2.9%    -2.9%           -            1,716                   1,675                  2.4%     2.4%            -
Intl                                             699              621                 12.6%    6.3%            6.3%         2,410                   2,302                  4.7%     2.7%            2.0%
WW                                               1,105            1,039               6.4%     2.6%            3.8%         4,126                   3,977                  3.7%     2.6%            1.1%
WOMEN’S HEALTH
US                                               3                3                   0.0%     0.0%            -            12                      19                     -36.8%   -36.8%          -
Intl                                             259              261                 -0.8%    -4.5%           3.7%         1,038                   1,048                  -1.0%    -3.1%           2.1%
WW                                               262              264                 -0.8%    -4.4%           3.6%         1,050                   1,067                  -1.6%    -3.7%           2.1%
WOUND CARE / OTHER
US                                               95               100                 -5.0%    -5.0%           -            437                     455                    -4.0%    -4.0%           -
Intl                                             85               76                  11.8%    6.1%            5.7%         342                     342                    0.0%     -1.7%           1.7%
WW                                               180              176                 2.3%     -0.1%           2.4%         779                     797                    -2.3%    -3.0%           0.7%
TOTAL CONSUMER
US                                               1,379            1,387               -0.6%    -0.6%           -            5,565                   5,420                  2.7%     2.7%            -
Intl                                             2,161            2,045               5.7%     1.2%            4.5%         8,037                   7,887                  1.9%     0.4%            1.5%
WW                                               $        3,540   $            3,432  3.1%     0.4%            2.7%         $             13,602    $             13,307   2.2%     1.3%            0.9%
See footnotes at end of schedule
                                                 REPORTED SALES vs. PRIOR PERIOD ($MM)
                                              FOURTH QUARTER                                                             TWELVE MONTHS
                                                                                      % Change                                                                             % Change
                                                 2017             2016                Reported Operational (1) Currency     2017                    2016                   Reported Operational (1) Currency
PHARMACEUTICAL SEGMENT (2) (3)
IMMUNOLOGY
US                                               $        2,227   $            2,157  3.2%     3.2%            -            $               8,871   $               8,846  0.3%     0.3%            -
Intl                                             859              779                 10.3%    5.2%            5.1%         3,373                   3,122                  8.0%     6.7%            1.3%
WW                                               3,086            2,936               5.1%     3.7%            1.4%         12,244                  11,968                 2.3%     2.0%            0.3%
REMICADE
US                                               1,073            1,173               -8.5%    -8.5%           -            4,525                   4,842                  -6.5%    -6.5%           -
US Exports (4)                                   115              109                 5.5%     5.5%            -            563                     782                    -28.0%   -28.0%          -
Intl                                             278              342                 -18.7%   -22.6%          3.9%         1,227                   1,342                  -8.6%    -10.2%          1.6%
WW                                               1,466            1,624               -9.7%    -10.5%          0.8%         6,315                   6,966                  -9.3%    -9.6%           0.3%
SIMPONI / SIMPONI ARIA
US                                               253              243                 4.1%     4.1%            -            954                     959                    -0.5%    -0.5%           -
Intl                                             237              183                 29.5%    25.1%           4.4%         879                     786                    11.8%    10.9%           0.9%
WW                                               490              426                 15.0%    13.1%           1.9%         1,833                   1,745                  5.0%     4.6%            0.4%
STELARA
US                                               740              632                 17.1%    17.1%           -            2,767                   2,263                  22.3%    22.3%           -
Intl                                             341              247                 38.1%    30.6%           7.5%         1,244                   969                    28.4%    27.2%           1.2%
WW                                               1,081            879                 23.0%    20.9%           2.1%         4,011                   3,232                  24.1%    23.7%           0.4%
OTHER IMMUNOLOGY
US                                               46               -                   *        *               -            62                      -                      *        *               -
Intl                                             3                7                   -57.1%   -57.1%          0.0%         23                      25                     -8.0%    -9.3%           1.3%
WW                                               49               7                   *        *               0.0%         85                      25                     *        *               1.3%
INFECTIOUS DISEASES
US                                               338              354                 -4.5%    -4.5%           -            1,358                   1,461                  -7.0%    -7.0%           -
Intl                                             462              407                 13.5%    5.9%            7.6%         1,796                   1,747                  2.8%     1.0%            1.8%
WW                                               800              761                 5.1%     1.0%            4.1%         3,154                   3,208                  -1.7%    -2.7%           1.0%
EDURANT / rilpivirine
US                                               14               14                  0.0%     0.0%            -            58                      52                     11.5%    11.5%           -
Intl                                             178              151                 17.9%    8.9%            9.0%         656                     521                    25.9%    23.1%           2.8%
WW                                               192              165                 16.4%    8.2%            8.2%         714                     573                    24.6%    22.1%           2.5%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US                                               285              283                 0.7%     0.7%            -            1,109                   1,143                  -3.0%    -3.0%           -
Intl                                             185              164                 12.8%    5.5%            7.3%         712                     708                    0.6%     -0.8%           1.4%
WW                                               470              447                 5.1%     2.4%            2.7%         1,821                   1,851                  -1.6%    -2.1%           0.5%
OTHER INFECTIOUS DISEASES
US                                               39               57                  -31.6%   -31.6%          -            191                     266                    -28.2%   -28.2%          -
Intl                                             99               92                  7.6%     1.5%            6.1%         428                     518                    -17.4%   -18.7%          1.3%
WW                                               138              149                 -7.4%    -11.1%          3.7%         619                     784                    -21.0%   -21.9%          0.9%
                                                 REPORTED SALES vs. PRIOR PERIOD ($MM)
                                              FOURTH QUARTER                                                             TWELVE MONTHS
                                                                                      % Change                                                                             % Change
                                                 2017             2016                Reported Operational (1) Currency     2017                    2016                   Reported Operational (1) Currency
NEUROSCIENCE
US                                               699              631                 10.8%    10.8%           -            2,630                   2,628                  0.1%     0.1%            -
Intl                                             825              839                 -1.7%    -5.3%           3.6%         3,356                   3,457                  -2.9%    -3.0%           0.1%
WW                                               1,524            1,470               3.7%     1.6%            2.1%         5,986                   6,085                  -1.6%    -1.6%           0.0%
CONCERTA / METHYLPHENIDATE
US                                               100              103                 -2.9%    -2.9%           -            384                     468                    -17.9%   -17.9%          -
Intl                                             103              101                 2.0%     -0.6%           2.6%         407                     395                    3.0%     2.8%            0.2%
WW                                               203              204                 -0.5%    -1.8%           1.3%         791                     863                    -8.3%    -8.4%           0.1%
INVEGA SUSTENNA / XEPLION / TRINZA / TREVICTA
US                                               436              360                 21.1%    21.1%           -            1,590                   1,343                  18.4%    18.4%           -
Intl                                             257              225                 14.2%    8.0%            6.2%         979                     871                    12.4%    11.6%           0.8%
WW                                               693              585                 18.5%    16.1%           2.4%         2,569                   2,214                  16.0%    15.7%           0.3%
RISPERDAL CONSTA
US                                               87               92                  -5.4%    -5.4%           -            360                     381                    -5.5%    -5.5%           -
Intl                                             110              118                 -6.8%    -11.5%          4.7%         445                     512                    -13.1%   -13.4%          0.3%
WW                                               197              210                 -6.2%    -8.8%           2.6%         805                     893                    -9.9%    -10.1%          0.2%
OTHER NEUROSCIENCE
US                                               76               76                  0.0%     0.0%            -            296                     436                    -32.1%   -32.1%          -
Intl                                             355              395                 -10.1%   -12.2%          2.1%         1,525                   1,679                  -9.2%    -8.7%           -0.5%
WW                                               431              471                 -8.5%    -10.2%          1.7%         1,821                   2,115                  -13.9%   -13.5%          -0.4%
ONCOLOGY
US                                               891              595                 49.7%    49.7%           -            3,098                   2,335                  32.7%    32.7%           -
Intl                                             1,148            867                 32.4%    26.0%           6.4%         4,160                   3,472                  19.8%    19.1%           0.7%
WW                                               2,039            1,462               39.5%    35.7%           3.8%         7,258                   5,807                  25.0%    24.6%           0.4%
DARZALEX
US                                               241              151                 59.6%    59.6%           -            884                     471                    87.7%    87.7%           -
Intl                                             130              49                  *        *               *            358                     101                    *        *               *
WW                                               371              200                 85.5%    82.3%           3.2%         1,242                   572                    *        *               *
IMBRUVICA
US                                               219              158                 38.6%    38.6%           -            841                     613                    37.2%    37.2%           -
Intl                                             303              188                 61.2%    52.2%           9.0%         1,052                   638                    64.9%    63.2%           1.7%
WW                                               522              346                 50.9%    46.0%           4.9%         1,893                   1,251                  51.3%    50.4%           0.9%
VELCADE
US                                               -                -                   -        -               -            -                       -                      -        -               -
Intl                                             271              274                 -1.1%    -5.6%           4.5%         1,114                   1,224                  -9.0%    -8.8%           -0.2%
WW                                               271              274                 -1.1%    -5.6%           4.5%         1,114                   1,224                  -9.0%    -8.8%           -0.2%
ZYTIGA
US                                               402              249                 61.4%    61.4%           -            1,228                   1,089                  12.8%    12.8%           -
Intl                                             353              270                 30.7%    25.0%           5.7%         1,277                   1,171                  9.1%     8.5%            0.6%
WW                                               755              519                 45.5%    42.5%           3.0%         2,505                   2,260                  10.8%    10.5%           0.3%
OTHER ONCOLOGY
US                                               29               37                  -21.6%   -21.6%          -            145                     162                    -10.5%   -10.5%          -
Intl                                             91               86                  5.8%     0.5%            5.3%         359                     338                    6.2%     5.6%            0.6%
WW                                               120              123                 -2.4%    -6.1%           3.7%         504                     500                    0.8%     0.4%            0.4%
PULMONARY HYPERTENSION(5)
US                                               365              -                   *        *               -            773                     -                      *        *               -
Intl                                             245              -                   *        *               -            554                     -                      *        *               -
WW                                               610              -                   *        *               -            1,327                   -                      *        *               -
OPSUMIT                                                           -
US                                               146              -                   *        *               -            320                     -                      *        *               -
Intl                                             123              -                   *        *               -            253                     -                      *        *               -
WW                                               269              -                   *        *               -            573                     -                      *        *               -
TRACLEER                                                          -
US                                               76               -                   *        *               -            161                     -                      *        *               -
Intl                                             91               -                   *        *               -            242                     -                      *        *               -
WW                                               167              -                   *        *               -            403                     -                      *        *               -
UPTRAVI                                                           -
US                                               117              -                   *        *               -            238                     -                      *        *               -
Intl                                             13               -                   *        *               -            25                      -                      *        *               -
WW                                               130              -                   *        *               -            263                     -                      *        *               -
OTHER(6)                                                          -
US                                               26               -                   *        *               -            54                      -                      *        *               -
Intl                                             18               -                   *        *               -            34                      -                      *        *               -
WW                                               44               -                   *        *               -            88                      -                      *        *               -
CARDIOVASCULAR / METABOLISM / OTHER
US                                                                  1,256               1,265               -0.7%            -0.7%            -                    4,744                   4,855                  -2.3%    -2.3%           -
Intl                                                                366                 338                 8.3%             3.2%             5.1%                 1,543                   1,541                  0.1%     0.5%            -0.4%
WW                                                                  1,622               1,603               1.2%             0.1%             1.1%                 6,287                   6,396                  -1.7%    -1.6%           -0.1%
XARELTO
US                                                                  710                 598                 18.7%            18.7%            -                    2,500                   2,288                  9.3%     9.3%            -
Intl                                                                -                   -                   -                -                -                    -                       -                      -        -               -
WW                                                                  710                 598                 18.7%            18.7%            -                    2,500                   2,288                  9.3%     9.3%            -
INVOKANA / INVOKAMET
US                                                                  221                 334                 -33.8%           -33.8%           -                    944                     1,273                  -25.8%   -25.8%          -
Intl                                                                46                  37                  24.3%            16.4%            7.9%                 167                     134                    24.6%    23.7%           0.9%
WW                                                                  267                 371                 -28.0%           -28.8%           0.8%                 1,111                   1,407                  -21.0%   -21.1%          0.1%
PROCRIT / EPREX
US                                                                  164                 186                 -11.8%           -11.8%           -                    675                     767                    -12.0%   -12.0%          -
Intl                                                                68                  73                  -6.8%            -12.1%           5.3%                 297                     338                    -12.1%   -13.0%          0.9%
WW                                                                  232                 259                 -10.4%           -11.9%           1.5%                 972                     1,105                  -12.0%   -12.3%          0.3%
OTHER(6)
US                                                                  161                 147                 9.5%             9.5%             -                    625                     527                    18.6%    18.6%           -
Intl                                                                252                 228                 10.5%            5.9%             4.6%                 1,079                   1,069                  0.9%     1.9%            -1.0%
WW                                                                  413                 375                 10.1%            7.3%             2.8%                 1,704                   1,596                  6.8%     7.5%            -0.7%
TOTAL PHARMACEUTICAL
US                                                                  5,776               5,002               15.5%            15.5%            -                    21,474                  20,125                 6.7%     6.7%            -
Intl                                                                3,905               3,230               20.9%            15.5%            5.4%                 14,782                  13,339                 10.8%    10.1%           0.7%
WW                                                                  $        9,681      $            8,232  17.6%            15.5%            2.1%                 $             36,256    $             33,464   8.3%     8.0%            0.3%
See footnotes at end of schedule
                                                                    REPORTED SALES vs. PRIOR PERIOD ($MM)
                                                 FOURTH QUARTER                                                                                                 TWELVE MONTHS
                                                                                                            % Change                                                                                              % Change
MEDICAL DEVICES SEGMENT (2)                                         2017                2016                Reported         Operational (1)  Currency             2017                    2016                   Reported Operational (1) Currency
CARDIOVASCULAR
US                                                                  $           286     $               247 15.8%            15.8%            -                    $               1,071   $                  948 13.0%    13.0%           -
Intl                                                                282                 238                 18.5%            15.6%            2.9%                 1,025                   901                    13.8%    14.0%           -0.2%
WW                                                                  568                 485                 17.1%            15.7%            1.4%                 2,096                   1,849                  13.4%    13.5%           -0.1%
DIABETES CARE
US                                                                  130                 191                 -31.9%           -31.9%           -                    612                     739                    -17.2%   -17.2%          -
Intl                                                                260                 271                 -4.1%            -9.3%            5.2%                 1,003                   1,050                  -4.5%    -5.8%           1.3%
WW                                                                  390                 462                 -15.6%           -18.7%           3.1%                 1,615                   1,789                  -9.7%    -10.5%          0.8%
DIAGNOSTICS
US                                                                  -                   -                   -                -                -                    -                       -                      -        -               -
Intl                                                                -                   -                   -                -                -                    1                       66                     *        *               *
WW                                                                  -                   -                   -                -                -                    1                       66                     *        *               *
ORTHOPAEDICS
US                                                                  1,389               1,422               -2.3%            -2.3%            -                    5,481                   5,521                  -0.7%    -0.7%           -
Intl                                                                950                 965                 -1.6%            -5.8%            4.2%                 3,777                   3,813                  -0.9%    -1.6%           0.7%
WW                                                                  2,339               2,387               -2.0%            -3.7%            1.7%                 9,258                   9,334                  -0.8%    -1.1%           0.3%
HIPS
US                                                                  215                 208                 3.4%             3.4%             -                    827                     798                    3.6%     3.6%            -
Intl                                                                149                 142                 4.9%             0.4%             4.5%                 567                     563                    0.7%     0.0%            0.7%
WW                                                                  364                 350                 4.0%             2.2%             1.8%                 1,394                   1,361                  2.4%     2.1%            0.3%
KNEES
US                                                                  246                 247                 -0.4%            -0.4%            -                    948                     943                    0.5%     0.5%            -
Intl                                                                151                 148                 2.0%             -2.5%            4.5%                 575                     581                    -1.0%    -1.6%           0.6%
WW                                                                  397                 395                 0.5%             -1.2%            1.7%                 1,523                   1,524                  -0.1%    -0.3%           0.2%
TRAUMA
US                                                                  397                 394                 0.8%             0.8%             -                    1,576                   1,545                  2.0%     2.0%            -
Intl                                                                272                 260                 4.6%             0.4%             4.2%                 1,040                   1,024                  1.6%     0.7%            0.9%
WW                                                                  669                 654                 2.3%             0.6%             1.7%                 2,616                   2,569                  1.8%     1.5%            0.3%
SPINE & OTHER
US                                                                  531                 573                 -7.3%            -7.3%            -                    2,130                   2,235                  -4.7%    -4.7%           -
Intl                                                                378                 415                 -8.9%            -13.0%           4.1%                 1,595                   1,645                  -3.0%    -3.6%           0.6%
WW                                                                  909                 988                 -8.0%            -9.7%            1.7%                 3,725                   3,880                  -4.0%    -4.2%           0.2%
SURGERY
US                                                                  1,076               1,023               5.2%             5.2%             -                    4,085                   4,026                  1.5%     1.5%            -
Intl                                                                1,482               1,364               8.7%             5.4%             3.3%                 5,474                   5,270                  3.9%     3.5%            0.4%
WW                                                                  2,558               2,387               7.2%             5.3%             1.9%                 9,559                   9,296                  2.8%     2.6%            0.2%
ADVANCED
US                                                                  430                 393                 9.4%             9.4%             -                    1,620                   1,524                  6.3%     6.3%            -
Intl                                                                593                 515                 15.1%            11.7%            3.4%                 2,136                   1,993                  7.2%     7.0%            0.2%
WW                                                                  1,023               908                 12.7%            10.8%            1.9%                 3,756                   3,517                  6.8%     6.7%            0.1%
GENERAL
US                                                                  452                 415                 8.9%             8.9%             -                    1,728                   1,669                  3.5%     3.5%            -
Intl                                                                718                 687                 4.5%             1.0%             3.5%                 2,735                   2,693                  1.6%     1.2%            0.4%
WW                                                                  1,170               1,102               6.2%             4.0%             2.2%                 4,463                   4,362                  2.3%     2.0%            0.3%
SPECIALTY
US                                                                  194                 215                 -9.8%            -9.8%            -                    737                     833                    -11.5%   -11.5%          -
Intl                                                                171                 162                 5.6%             3.1%             2.5%                 603                     584                    3.3%     2.4%            0.9%
WW                                                                  365                 377                 -3.2%            -4.3%            1.1%                 1,340                   1,417                  -5.4%    -5.8%           0.4%
VISION CARE
US                                                                  433                 265                 63.4%            63.4%            -                    1,575                   1,032                  52.6%    52.6%           -
Intl                                                                686                 456                 50.4%            48.2%            2.2%                 2,488                   1,753                  41.9%    42.0%           -0.1%
WW                                                                  1,119               721                 55.2%            53.8%            1.4%                 4,063                   2,785                  45.9%    46.0%           -0.1%
CONTACT LENSES / OTHER
US                                                                  290                 265                 9.4%             9.4%             -                    1,122                   1,032                  8.7%     8.7%            -
Intl                                                                510                 456                 11.8%            9.6%             2.2%                 1,914                   1,753                  9.2%     9.3%            -0.1%
WW                                                                  800                 721                 11.0%            9.6%             1.4%                 3,036                   2,785                  9.0%     9.1%            -0.1%
SURGICAL
US                                                                  143                 -                   *                *                -                    453                     -                      *        *               -
Intl                                                                176                 -                   *                *                -                    574                     -                      *        *               -
WW                                                                  319                 -                   *                *                -                    1,027                   -                      *        *               -
TOTAL MEDICAL DEVICES
US                                                                  3,314               3,148               5.3%             5.3%             -                    12,824                  12,266                 4.5%     4.5%            -
Intl                                                                3,660               3,294               11.1%            7.5%             3.6%                 13,768                  12,853                 7.1%     6.7%            0.4%
WW                                                                  $        6,974      6,442               8.3%             6.5%             1.8%                 $             26,592    $             25,119   5.9%     5.7%            0.2%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Prior year amounts have been reclassified to conform to current year product disclosure
(4) Reported as U.S. sales
(5) Actelion acquisition completed June 16, 2017
(6) All non-PAH Actelion products were reclassified to Other within the Cardiovascular/Metabolisim/Other therapeutic area. See supplementary schedule.
Pharmaceutical Supplemental Schedule
Prior quarter amounts have been reclassified to
conform to current quarter product disclosure  ($MM)
                                                     2017
                                                                      Q2                Q3
PHARMACEUTICAL SEGMENT(1)
PULMONARY HYPERTENSION
US                                                                    37                371
Intl                                                                  48                261
WW                                                                    85                632
OTHER(2)
US                                                                    3                 25
Intl                                                                  2                 14
WW                                                                    5                 39
CARDIOVASCULAR / METABOLISM / OTHER
US                                                                    1,214             1,179
Intl                                                                  391               406
WW                                                                    1,605             1,585
OTHER(3)
US                                                                    142               156
Intl                                                                  271               291
WW                                                                    413               447
(1) Unaudited
(2) All non-PAH Actelion products removed; Previously included All Other PAH & Non-PAH products.
(3) Includes Actelion non-PAH products; Previously included in Pulmonary Hypertension Other.

https://mma.prnewswire.com/media/403394/Johnson_and_Johnson_Logo.jpg

https://c212.net/c/img/favicon.png?sn=NY94908&sd=2018-01-23

View original content with multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-reports-2017-fourth-quarter-results-300586431.html

SOURCE Johnson & Johnson

https://rt.prnewswire.com/rt.gif?NewsItemId=NY94908&Transmission_Id=201801230640PR_NEWS_USPR_____NY94908&DateId=20180123



Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2018 StockSelector.com. All rights reserved.